PRAME overexpression predicts good outcome in pediatric B-ALL receiving chemotherapy. PRAME overexpression predicts good outcome in B-ALL with non-poor cytogenetic risk. PRAME expression has no impact on outcome in pediatric T-ALL receiving chemotherapy.